Key Takeaways
- Arjun Kampani, SVP and General Counsel at Rocket Lab, offloaded 88,000 RKLB shares on June 18 at $107.98 per share, netting approximately $9.5 million.
- Kampani’s sale trimmed his holdings by nearly 25%; he retains 264,705 shares valued at around $28.6 million.
- Shares declined to $107.24 on unusually heavy trading volume — roughly three times the daily average.
- The aerospace company delivered 63.4% revenue growth year-over-year in Q1 and surpassed Wall Street projections.
- RKLB will officially enter the Nasdaq-100 index on June 22, potentially attracting significant institutional capital.
Arjun Kampani, Senior Vice President and General Counsel at Rocket Lab (RKLB), executed a significant stock sale on June 18, disposing of 88,000 shares at an average transaction price of $107.98. The move generated proceeds of roughly $9.5 million.
After completing the transaction, Kampani maintains direct ownership of 264,705 shares, currently worth approximately $28.6 million based on recent trading prices. The sale constitutes a 24.95% decrease in his direct equity position.
This transaction is part of an established pattern. Kampani previously sold 28,668 shares on May 26 at $142.57 each, followed by 70,000 shares on May 27 at $145.13, and an additional 23,804 shares on May 28 at $147.43.
Throughout the past twelve months, he has divested a combined 342,714 shares. During this identical timeframe, insider purchase activity has been completely absent, while the company has recorded 43 separate insider sales transactions.
RKLB stock declined $0.74 during the session, settling at $107.24. Trading activity surged to 70.2 million shares — approximately three times the typical daily volume of 24.8 million shares.
Share Price Maintains Elevated Position Despite Retreat
Notwithstanding recent weakness, RKLB continues trading substantially above its 200-day moving average of $82.68 and its 50-day moving average of $104.00. The equity has established a 52-week trading range between $27.84 and $151.00.
The company commands a market capitalization of $62.07 billion. Its price-to-earnings ratio registers at -335.12, signaling the firm has yet to achieve profitability. With a beta coefficient of 2.49, the stock exhibits considerably higher volatility compared to broader market indices.
Wall Street analysts maintain an average price target of $102.76 alongside a “Moderate Buy” consensus recommendation. Individual targets span from $105 (KGI Securities, neutral stance) to $150 (New Street Research, buy rating). Stifel Nicolaus has established a $132 objective, while KeyCorp recently elevated its rating to overweight with a $135 price target.
Robust Operational Performance Contrasts with Valuation Concerns
During its latest quarterly earnings release on May 7, Rocket Lab reported revenue totaling $200.35 million, exceeding analyst consensus estimates of $189.65 million by approximately $10.7 million.
Top-line growth reached 63.4% compared to the prior-year period. Earnings per share registered at -$0.07, aligning precisely with expectations. The company maintains a substantial $2.2 billion contract backlog.
Rocket Lab recently achieved a significant milestone by successfully completing a critical Space Development Agency review, bolstering its position within defense sector programs.
Commencing June 22, RKLB will officially join the Nasdaq-100 index composition. This inclusion generally catalyzes automatic purchasing activity from passive index funds and exchange-traded funds that replicate the benchmark.
Institutional investors collectively control 71.78% of outstanding shares. Vanguard manages 47.4 million shares, Baillie Gifford possesses 17.9 million, and Capital World Investors maintains a position of 16.2 million shares.
GuruFocus calculates the company’s intrinsic value at $26.42, resulting in a price-to-GF-Value multiple of 4.09 — a metric the platform categorizes as significantly overvalued.
Sell-side research analysts anticipate full-year earnings per share of -$0.29 for the current fiscal period.
